IP Library Granted Patent US 9,840,693
Granted Patent B2
US 9,840,693 · App. 15/411,125 · Granted Dec 12, 2017

Polypeptide hydrogels and uses related thereto

Inventors: Michael E. Davis (Atlanta, GA); Archana V. Boopathy (Lilburn, GA)
Assignees: Emory University; Georgia Tech Research Corporation
C12N5/0657C12N5/0068C12N2501/42C12N2533/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,840,693
App. No.
15/411,125
Granted
Dec 12, 2017
Kind
B2
Abstract

This disclosure relates to self-assembling peptides that form hydrogels comprising peptide sequences for the activation of signaling pathways. In certain embodiments, the disclosure relates to compositions comprising a recombinant polypeptide comprising a cell signaling sequence, e.g., JAG-1 sequence, fused to a hydrogel polypeptide sequence. In certain embodiments, the disclosure relates to methods of cell culture on three dimensional scaffolds/hydrogels composed of self-assembling peptides disclosed herein.

Claims (10)

1. A method of growing cells comprising placing an isolated cell on or in a hydrogel under conditions such that the cell replicates,

wherein hydrogel comprises a recombinant polypeptide in combination with a hydrogel polypeptide,

wherein the recombinant polypeptide comprises a cell signaling sequence, wherein the cells signal sequence comprises SEQ ID NO: 1, fused to a hydrogel polypeptide sequence,

wherein the hydrogel polypeptide and the recombinant polypeptide are in a ratio of between 1:5 to 1:15 by weight, and

wherein the hydrogel polypeptide and the recombinant peptide are 1.5% to 2.5% by weight to volume of the hydrogel.

2. The method of claim 1 , wherein the isolated cell is a stem cell, progenitor cell, cardiac stem cell, cardiac progenitor cell, bone marrow derived cell, or mesenchymal stem cell.

3. The method of claim 2 , wherein the cardiac progenitor cell is isolated by the process of selecting cells for stem cell surface markers, progenitor cell surface markers, or cardiac cell surface markers.

4. The method of claim 1 , wherein the hydrogel comprises a saccharide at a concentration of between 100 nm to 500 mM.

5. The method of claim 1 , wherein the hydrogel comprises a buffer creating a pH of between 7.0 to 7.7.

6. The method of claim 1 , wherein the hydrogel further comprising a cardiac progenitor cell.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 31, 2017
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041565/0522 →
Continuity (3)
Division 14602839 · Jan 22, 2015
Provisional Application 61930713 · Jan 23, 2014
Related Publication 20170137785A1 · May 18, 2017